Battistina Asproni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2868201/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction. Molecules, 2021, 26, 2126.	3.8	4
2	Biological Effects on μ-Receptors Affinity and Selectivity of Arylpropenyl Chain Structural Modification on Diazatricyclodecane Derivatives. Molecules, 2021, 26, 5448.	3.8	1
3	Synthesis, biological evaluation and docking studies of a novel class of sulfur-bridged diazabicyclo[3.3.1]nonanes. Bioorganic Chemistry, 2020, 102, 104072.	4.1	1
4	Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands. Molecules, 2019, 24, 1656.	3.8	5
5	Pyridinyl- and pyridazinyl-3,6-diazabicyclo[3.1.1]heptane-anilines: Novel selective ligands with subnanomolar affinity for α4β2 nACh receptors. European Journal of Medicinal Chemistry, 2018, 152, 401-416.	5.5	8
6	Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinoneâ€Based Cannabinoid Receptor Typeâ€2 Ligands. ChemMedChem, 2018, 13, 1102-1114.	3.2	1
7	Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB 1 receptor ligand antagonists. Bioorganic and Medicinal Chemistry, 2018, 26, 295-307.	3.0	8
8	Novel pyrrolocycloalkylpyrazole analogues as CB ₁ ligands. Chemical Biology and Drug Design, 2018, 91, 181-193.	3.2	4
9	New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. European Journal of Medicinal Chemistry, 2017, 127, 398-412.	5.5	15
10	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB 2 receptor antagonists/inverse agonists. Bioorganic and Medicinal Chemistry, 2016, 24, 5291-5301.	3.0	15
11	Synthesis and Antineoplastic Evaluation of Novel Unsymmetrical 1,3,4-Oxadiazoles. Journal of Medicinal Chemistry, 2016, 59, 10451-10469.	6.4	31
12	Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. European Journal of Medicinal Chemistry, 2016, 112, 66-80.	5.5	18
13	Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors. European Journal of Medicinal Chemistry, 2014, 84, 181-193.	5.5	37
14	Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: A versatile architecture for CB2 selective ligands. European Journal of Medicinal Chemistry, 2014, 82, 281-292.	5.5	16
15	Different Classes of CB2 Ligands Potentially Useful in the Treatment of Pain. Recent Patents on CNS Drug Discovery, 2013, 8, 42-69.	0.9	22
16	Chemistry of Tricyclic-based Heterocycles as Useful Scaffolds for Phosphodiesterase 10A Ligands. Mini-Reviews in Organic Chemistry, 2013, 10, 123-140.	1.3	4
17	A Survey of Recent Patents on CB2 Agonists in the Management of Pain. Recent Patents on CNS Drug Discovery, 2012, 7, 4-24.	0.9	11
18	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. Open Medicinal Chemistry Journal, 2012, 6, 1-14.	2.4	12

BATTISTINA ASPRONI

#	Article	IF	CITATIONS
19	Synthesis and Pharmacological Evaluation of Novel 4-Alkyl-5-thien-2'-yl Pyrazole Carboxamides. Central Nervous System Agents in Medicinal Chemistry, 2012, 12, 254-276.	1.1	27
20	Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 642-649.	3.0	53
21	Ethyl 2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-4-imidazolecarboxylate is a novel positive modulator of GABAA receptors. European Journal of Pharmacology, 2005, 516, 204-211.	3.5	9
22	Synthesis, Structureâ^'Activity Relationships at the GABAAReceptor in Rat Brain, and Differential Electrophysiological Profile at the Recombinant Human GABAAReceptor of a Series of Substituted 1,2-Diphenylimidazoles. Journal of Medicinal Chemistry, 2005, 48, 2638-2645.	6.4	22
23	Synthesis and Pharmacological Evaluation of 1-[(1,2-Diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with Clozapine-Like Mixed Activities at Dopamine D2, Serotonin, and GABAAReceptors. Journal of Medicinal Chemistry, 2002, 45, 4655-4668.	6.4	27